1. Scrip
  2. >>R&D
  3. >>Clinical Trials

The Bar Is Raised At ASCO For ADC Developers

 
• By Lucie Ellis-Taitt

Multiple early-stage data presentations at ASCO for antibody-drug conjugates in solid tumors highlight that clinical data success measures need to be tougher to push developers towards treatment-altering breakthroughs.

Mountain
ADC developers need to aim higher with early stage cancer therapies

Drug developers were challenged to strive for new heights with novel antibody-drug conjugates in solid cancers during a discussion session at the 2017 American Society of Clinical Oncology (ASCO) annual meeting, held June 2-6 in Chicago.

The session focused on three early-stage clinical data presentations for novel antibody-drug conjugates (ADCs) from Seattle Genetics Inc., Daiichi Sankyo Co. Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D